Treatment of refractory thyroid cancer

Berdelou, A.; Lamartina, Livia; Klain, Michele; Leboulleux, Sophie; Schlumberger, Martin; _, _

doi:10.1530/erc-17-0542

Cited by 69 publications

(46 citation statements)

References 89 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… 5 PTC develops slowly and can be cured by surgery, thyroid hormone therapy and 131 I isotope therapy. 6 Most PTC patients have good prognosis with the 10-year survival rate reaching 90%. 7 , 8 Because of the serious potential side effects of radioactive iodine and patients’ neglect of the PTC prognosis, some PTC patients suffer from recurrence and some PTCs may develop distant metastases with high mortality.…”

Section: Introductionmentioning

confidence: 99%

Molecular characterization of papillary thyroid carcinoma: a potential three-lncRNA prognostic signature

You¹,

Yang²,

Sui³

et al. 2018

CMAR

View full text Add to dashboard Cite

PurposePapillary thyroid carcinoma (PTC), the most frequent type of malignant thyroid tumor, lacks novel and reliable biomarkers of patients’ prognosis. In the current study, we mined The Cancer Genome Atlas (TCGA) to develop lncRNA signature of PTC.Patients and methodsThe intersection of PTC lncRNAs was obtained from the TCGA database using integrative computational method. By the univariate and multivariate Cox analysis, key lncRNAs were identified to construct the prognostic model. Then, all patients were divided into the high-risk group and low-risk group to perform the Kaplan–Meier (K–M) survival curves and time-dependent receiver operating characteristic (ROC) curve, estimating the prognostic power of the prognostic model. Functional enrichment analysis was also performed. Finally, we verified the results of the TCGA analysis by the Gene Expression Omnibus (GEO) databases and quantitative real-time PCR (qRT-PCR).ResultsAfter the comprehensive analysis, a three-lncRNA signature (PRSS3P2, KRTAP5-AS1 and PWAR5) was obtained. Interestingly, patients with low-risk scores tended to gain obviously longer survival time, and the area under the time-dependent ROC curve was 0.739. Furthermore, gene ontology (GO) and pathway analysis revealed the tumorigenic and prognostic function of the three lncRNAs. We also found three potential transcription factors to help understand the mechanisms of the PTC-specific lncRNAs. Finally, the GEO databases and qRT-PCR validation were consistent with our TCGA bioinformatics results.ConclusionWe built a three-lncRNA signature by mining the TCGA database, which could effectively predict the prognosis of PTC.

show abstract

Section: Introductionmentioning

confidence: 99%

Molecular characterization of papillary thyroid carcinoma: a potential three-lncRNA prognostic signature

You¹,

Yang²,

Sui³

et al. 2018

CMAR

View full text Add to dashboard Cite

show abstract

“…Several retrospective studies have not found any benefit for RAI treatment in terms of DFS or OS in low-risk patients (Lamartina et al 2015). On the other hand, the rare patients with evidence of structural residual disease after surgery are candidates for a high activity (3.7 GBq) RAI treatment (Berdelou et al 2018).…”

Section: Post-operative Administration Of Raimentioning

confidence: 99%

“…It included total thyroidectomy and post-operative administration of a high activity of radioactive iodine (RAI) followed by suppressive levothyroxine therapy (Mazzaferri & Jhiang 1994). This type of aggressive strategy is still appropriate for high-risk DTCs (Berdelou et al 2018, but for the vast majority of tumors currently diagnosed that have a low risk of mortality and of recurrence, there is no convincing evidence that aggressive treatment is beneficial (Hay et al 2018). Consequently, the current trend is toward the use of a more limited approach for these tumors, which still permits a reliable follow-up (Lamartina et al 2018a).…”

Section: Introductionmentioning

confidence: 99%

An update on the management of low-risk differentiated thyroid cancer

Lamartina

Leboulleux

Terroir

et al. 2019

Endocrine-Related Cancer

Self Cite

View full text Add to dashboard Cite

Low-risk papillary cancers, which represent the vast majority of thyroid cancers diagnosed today, do not require aggressive treatment or follow-up. Initial treatment consists of a total thyroidectomy without prophylactic lymph node dissection. A hemithyroidectomy is an alternative in some patients with an intrathyroidal tumor and with a normal contralateral lobe at pre-operative neck ultrasonography. The use of post-operative radioiodine should be restricted to selected patients. Follow-up at 6-18 months is based on serum thyroglobulin (Tg), Tg-antibody determination and neck ultrasonography. In the absence of any abnormality (excellent response to treatment), the risk of recurrence is extremely low and follow-up may consist of serum TSH monitoring that is maintained in the normal range, and a Tg and Tg-antibody titer determination every year. There is no need for referral to a specialized center. In patients with detectable serum Tg or detectable Tg antibodies, the trend over time of these markers on levothyroxine treatment will dictate subsequent follow-up: a decreasing trend is reassuring, but an increasing trend should lead to imaging, starting with neck ultrasonography.

show abstract

“…Thyroid cancer (TC) is a very common endocrine malignancy, [ 1 – 3 ] which is characterized by different biological and clinical features. [ 4 – 6 ] It is also the leading cause of mortality and morbidity around the world. [ 7 – 8 ] It consists of 4 subtypes of papillary thyroid cancer, follicular thyroid cancer, medullary thyroid cancer, and anaplastic thyroid cancer.…”

Section: Introductionmentioning

confidence: 99%

Effect of high-quality nursing on alleviating depression and anxiety in patients with thyroid cancer during perioperative period

Cui

2020

Medicine

View full text Add to dashboard Cite

Background: This study will assess the effect of high-quality nursing (HQN) on alleviating depression and anxiety (DA) in patients with thyroid cancer (TC) during perioperative period (PPP). Methods: We will search the following electronic databases (MEDLINE, EMBASE, PsycINFO, Cochrane Library, CINAHL, Web of Science, CBM, WANGFANG, and CNKI) from inception to the present and other literature sources without language limitation. All potential randomized controlled trials reporting on effect of HQN on DA in patients with TC during PPP will be considered for inclusion. Two researchers will separately carry out study selection, data extraction, and study quality evaluation. Any different opinion will be solved by a third author through discussion. All statistical analysis will be performed by RevMan 5.3 software. Results: We will appraise the effect of HQN on DA in patients with TC during PPP through assessing outcomes of depression, anxiety, pressure, quality of life, and adverse events. Conclusion: This study will provide evidence to determine whether HQN is effective or not on DA in patients with TC during PPP. OSF registration: osf.io/sb5r8.

show abstract

Treatment of refractory thyroid cancer

Cited by 69 publications

References 89 publications

Molecular characterization of papillary thyroid carcinoma: a potential three-lncRNA prognostic signature

Molecular characterization of papillary thyroid carcinoma: a potential three-lncRNA prognostic signature

An update on the management of low-risk differentiated thyroid cancer

Effect of high-quality nursing on alleviating depression and anxiety in patients with thyroid cancer during perioperative period

Contact Info

Product

Resources

About